Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence

NIH RePORTER · NIH · P50 · $202,553 · view on reporter.nih.gov ↗

Abstract

The overall goal of this project is to perform preclinical and phase II clinical testing of a Th17-induced pulsed dendritic cell vaccine to assess its efficacy in preventing relapse of high grade ovarian cancer in first remission after debulking surgery and platinum-based adjuvant or neoadjuvant chemotherapy.

Key facts

NIH application ID: 11041232
Project number: 5P50CA136393-14
Recipient: MAYO CLINIC ROCHESTER
Principal Investigator: Matthew Stephen Block
Activity code: P50
Funding institute: NIH
Fiscal year: 2024
Award amount: $202,553
Award type: 5
Project period: 2009-07-01 → 2026-08-31